Skip to main content

Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · Delayed Price · USD
2.74
-0.06 (-2.14%)
At close: Dec 6, 2021 4:00 PM
2.76
0.02 (0.73%)
Pre-market:Dec 7, 2021 9:03 AM EST
Market Cap59.97M
Revenue (ttm)n/a
Net Income (ttm)-1.55M
Shares Out21.89M
EPS (ttm)-0.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,284,009
Open2.83
Previous Close2.80
Day's Range2.53 - 2.99
52-Week Range2.10 - 8.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About KTTA

Pasithea Therapeutics is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. As of March 26, 2021, the Company had not commenced core operations. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. Our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing n...

IndustryBiotechnology
IPO DateSep 15, 2021
CEODr. Tiago Reis Marques
Employees1
Stock ExchangeNASDAQ
Ticker SymbolKTTA
Full Company Profile

News

Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals --

6 days ago - GlobeNewsWire

Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Un...

MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...

1 week ago - GlobeNewsWire

Pasithea Stock Plunges After Equity Raise of $30M

Pasithea Therapeutics Corp (NASDAQ: KTTA) shares shed their gains from yesterday after it announced a private offering of 8.68 million shares and warrants to purchase 8.68 million shares. The offer pric...

1 week ago - Benzinga

Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market ...

MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...

1 week ago - GlobeNewsWire

KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today

Pasithea Therapeutics (KTTA) stock is rocketing higher on Tuesday after adding esketamine nasal spray to its U.K. offerings. The post KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therap...

1 week ago - InvestorPlace

Hot Penny Stocks Today: Why Is KTTA Stock Moving?

Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving?

1 week ago - PennyStocks

Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.

Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders Pasithea Clinics is one of only three a...

2 weeks ago - GlobeNewsWire

Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders – – Pasithea Clinics commences IV ketamine infusion therapy in Knightsbri...

1 month ago - GlobeNewsWire

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

-- Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders -- -- Ketamine in sub-a...

1 month ago - GlobeNewsWire

Pasithea Therapeutics: Revenues Just Around the Corner

Pasithea Therapeutics ( KTTA , Financial) ( KTTAW , Financial) caught my eye recently as an emerging biotech player with a different approach to business. On first impression, the company may seem like ...

1 month ago - GuruFocus

Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery

Photo by CDC on Unsplash Pasithea Therapeutics ( NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its research partner to help di...

1 month ago - Benzinga

Pasithea, Evotec Ink Drug Development Pact

Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner. No deal terms were disclosed.

1 month ago - Benzinga

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement.

-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Com...

1 month ago - Benzinga

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

-- Company contracts leading global drug development company to advance initial drug candidate -- -- Company contracts leading global drug development company to advance initial drug candidate --

1 month ago - GlobeNewsWire